featured
Brentuximab Vedotin vs Physician's Choice in Cutaneous T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Blood Adv 2021 Dec 14;5(23)5098-5106, SM Horwitz, JJ Scarisbrick, R Dummer, S Whittaker, M Duvic, YH Kim, P Quaglino, PL Zinzani, O Bechter, H Eradat, L Pinter-Brown, OE Akilov, L Geskin, JA Sanches, PL Ortiz-Romero, M Weichenthal, DC Fisher, J Walewski, J Trotman, K Taylor, S Dalle, R Stadler, J Lisano, V Bunn, M Little, HM PrinceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.